Showing posts with label Drugs. Show all posts
Showing posts with label Drugs. Show all posts

Tuesday, April 24, 2012

Migraine Headaches: New Guidelines Focus on Prevention

health tips
Doctor finds new guidelines on migraine headaches' prevention
From prescription pills to poisonous plants, plenty of treatments can help prevent migraines, according to new guidelines from the American Academy of Neurology.

The updated guidelines could help some of the country's 30 million "migraineurs" reduce the frequency and severity of their headaches.

"About 38 percent of people who suffer from migraines could benefit from preventive treatments, but only less than a third of these people currently use them," said Dr. Stephen Silberstein, director of the Jefferson Headache Center at Thomas Jefferson University in Philadelphia and lead author of the guidelines released today.

Migraines are a type of headache often accompanied by nausea, sensitivity to sound and "aura," or visual symptoms. Acute treatments can ease the ache once it's started. But people with frequent migraines are advised to try daily therapies to prevent the pain and dampen the dread of when and where the next headache will hit.

"People who have relatively mild migraines that come infrequently and respond well to acute treatments, those people don't need preventive therapy," said Dr. Richard Lipton, director of the Montefiore Headache Center in New York City. "But if you're losing more than 10 days per month to your migraines, it's probably worth taking medication on a daily basis."

Silberstein and colleagues reviewed the slew of studies on migraine prevention to tease out treatments that were proved to work from ones that were probably ineffective. Among those with "established efficacy" were anti-seizure drugs such as topiramate, blood pressure-lowering drugs called beta-blockers, and inflammation-blocking extracts from the toxic butterbur plant.

"There are many, many different treatments and they have many effects on brain physiology," said Dr. Joel Saper, director of the Michigan Headache and Neurological Institute in Ann Arbor. "Some people need one kind of an effect to feel better; some need another. Some need multiple treatments at the same time."

Preventive treatments that are considered "probably effective" include antidepressants such as amitriptyline, over-the-counter painkillers such as ibuprofen, and natural supplements such as riboflavin.

"Some people say, 'I really don't want be on a medication," said Dr. Audrey Halpern, a neurologist at NYU Langone's Joan H. Tisch Center for Women's Health in New York City. "It may be appropriate for them to start with a natural supplement or other complementary therapy to get them going."

But Halpern stressed that "natural" doesn't necessarily mean "safe."

"Some supplements may interact with other medications," she said. "It's really important for people to talk to their doctors before starting any therapy."

One natural supplement, butterbur extract, has been used to treat migraine for more than 500 years. But only recently was its migraine-fighting potential proved in a clinical trial.

"The great thing about butterbur is it has a very favorable side effect profile," said Lipton, cautioning that supplements were not regulated by the U.S. Food and Drug Administration. "One of the issues with natural compounds is they're very complex. It's a very complex biochemical soup."

Some of the treatments listed in the guidelines are FDA-approved to treat migraines. But many are approved for other conditions and used off-label in migraineurs.

"The fascinating thing about migraine prevention is almost all the therapies we have were developed for another purpose and discovered to work in migraine prevention by chance alone," said Lipton, describing how drugs designed for epilepsy and hypertension were found to work haphazardly in headache sufferers. "But I think we're moving into an era where we can develop designer drugs specifically for migraine."

The new guidelines are similar to those from 2000 with a few changes: Topiramate is now considered effective in migraine prevention; and gabapentin and verapamil were downgraded from "probably effective" to a category of treatments with "inadequate" evidence to support or refute its use. But experts emphasize the guidelines are not the be-all, end-all.

"They're useful as a starting point," said Saper, adding that difficult cases often required drugs not listed in general guidelines. "Many people respond well to drugs that don't help most other people, and those drugs don't get listed because there's not enough evidence of a generalized benefit."

News by ABC News

Read current news at

Sunday, March 04, 2012

Global drug industry tightens anti-corruption code

(Reuters) - The global pharmaceutical industry is tightening its code of practice in a bid to stamp out bribery and corruption, particularly in emerging markets.

The International Federation of Pharmaceutical Manufacturers and Associations said on Thursday it had expanded and strengthened the code to ensure "the highest ethical and professional standards."

Bribes paid to foreign doctors and other state employees are shaping up as a major legal liability threat for Big Pharma, which has already forked out billions of dollars to settle mis-selling scandals in the United States.

Johnson & Johnson settled for $78 million with British and U.S. authorities last April, after disclosing payments to doctors in Greece, Poland and Romania, while Pfizer reached an outline deal in a separate case late last year.

The new IFPMA code extends the rules covering drug company behavior to also include interactions with medical institutions and patient organizations, as well as healthcare professionals, such as prescribing doctors.

It also makes clearer the dividing line between promotional aid and items of medical utility - which are allowed, and personal and cash gifts - which are not.

Permitted payments for entertainment are being curtailed, although they will still be allowed when interactions with drug firms are of a scientific or educational nature, including events at large medical meetings.

"The new code provides a framework for the industry to act with integrity and build trust," said IFPMA President and AstraZeneca CEO David Brennan. "This is not about doing the easy thing, but the right thing."

The Geneva-based organization sees a particular role for its expanded code of practice in thinly regulated and smaller emerging markets, where national pharmaceutical organizations may have no presence.

But Tim Reed, director of Health Action International, an Amsterdam-based group that is critical of many industry practices, is not convinced the IFPMA has the teeth to make sure its edicts are implemented on the ground.

In the five years since the publication of the last code, the IFPMA has examined only four complaints against member companies - although more cases have been taken up by national organizations.

"There is a difference between intent and action," Reed said. "When you drill down to what is happening in developing countries, it is clear that it is just not applied. There is a real problem with enforcement because there is no punitive action as a result of transgression."

Read current news at